Vivo Opportunity increases InMed (INM) stake with open-market share buys
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
InMed Pharmaceuticals Inc. reported that investment entities affiliated with Vivo Opportunity made a series of open-market purchases of its Common Shares. Over June 30 to July 2, 2026, Vivo Opportunity Cayman Fund, L.P. and Vivo Opportunity Fund Holdings, L.P. together bought 6,551 shares at weighted average prices around $1.54–$1.55 per share in multiple transactions within stated price ranges. Following these purchases, Cayman Fund indirectly held 73,135 shares and Fund Holdings indirectly held 724,395 shares, with general partners Vivo Opportunity, LLC and Vivo Opportunity Cayman, LLC disclaiming beneficial ownership except for their pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 6,551 shares ($10,148)
Net Buy
6 txns
Insider
Vivo Opportunity, LLC, Vivo Opportunity Fund Holdings, L.P., Vivo Opportunity Cayman, LLC, Vivo Opportunity Cayman Fund, L.P.
Role
null | null | null | null
Bought
6,551 shs ($10K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Shares | 1,460 | $1.55 | $2K |
| Purchase | Common Shares | 147 | $1.55 | $227.85 |
| Purchase | Common Shares | 3,946 | $1.55 | $6K |
| Purchase | Common Shares | 398 | $1.55 | $616.90 |
| Purchase | Common Shares | 545 | $1.54 | $839.30 |
| Purchase | Common Shares | 55 | $1.54 | $84.70 |
Holdings After Transaction:
Common Shares — 724,395 shares (Indirect, By Vivo Opportunity Fund Holdings, L.P.)
Footnotes (1)
- Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.52 to $1.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4. The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.51 to $1.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4. The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.55 to $1.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (5) to this Form 4.
Key Figures
Total shares purchased: 6,551 shares
Cayman Fund holding: 73,135 shares
Fund Holdings holding: 724,395 shares
+5 more
8 metrics
Total shares purchased
6,551 shares
Net open-market purchases June 30–July 2, 2026
Cayman Fund holding
73,135 shares
Indirect InMed common shares after July 2, 2026 trades
Fund Holdings holding
724,395 shares
Indirect InMed common shares after July 2, 2026 trades
Cayman Fund July 2 purchase
147 shares at $1.55/share
Open-market purchase on July 2, 2026
Fund Holdings July 2 purchase
1,460 shares at $1.55/share
Open-market purchase on July 2, 2026
Price range F3 footnote
$1.52–$1.59/share
Multiple open-market trades in one transaction group
Price range F4 footnote
$1.51–$1.59/share
Multiple open-market trades in one transaction group
Price range F5 footnote
$1.55–$1.60/share
Multiple open-market trades in one transaction group
Key Terms
open-market purchase, weighted average price, beneficial ownership, pecuniary interest, +1 more
5 terms
open-market purchase financial
"These shares were acquired on the open market in multiple transactions"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
weighted average price financial
"The price reported herein is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
beneficial ownership financial
"disclaims beneficial ownership over such securities except to the extent of its pecuniary interest"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein"
Section 16 regulatory
"shall not be deemed an admission of beneficial ownership ... for purposes of Section 16"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
FAQ
What insider transactions did Vivo Opportunity report for InMed (INM)?
Vivo Opportunity-related funds reported open-market purchases of InMed common shares. Across June 30 to July 2, 2026, they bought a combined 6,551 shares at weighted average prices around $1.54–$1.55 per share, increasing their indirect ownership stakes.
What does the Form 4 say about beneficial ownership for Vivo Opportunity and InMed (INM)?
The Form 4 explains that Vivo Opportunity, LLC and Vivo Opportunity Cayman, LLC are general partners of the record holder funds. Each entity disclaims beneficial ownership of the securities except to the extent of its pecuniary interest in those partnership holdings.